Published in Medical Letter on the CDC and FDA, September 16th, 2007
Under the terms of an agreement with Apotex, Inc., Barr will manufacture the product and Apotex will market it in Canada. Apotex will record the Canadian sales of Portia and will pay Barr a royalty from those sales.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA